SCHEMBL1489970

SCHEMBL1489970

CCOc1ccc(S(=O)(=O)Cl)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.53
MAPK1 P28482 4/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 3/20 0.46
HTT P42858 3/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 4/20 0.45
CALM1 P0DP23 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2564265 0.91 ALDH1A1 (0.47) TSHRPOLBMAPTGAALMNA
SCHEMBL66188 0.86 TSHR (0.70) TSHRMAPK1POLBLMNAHTT
SCHEMBL8663655 0.81 MAPK1 (0.47) TSHRMAPK1POLBMAPTLMNA
SCHEMBL1949836 0.81 HTT (0.57) TSHRPOLBMAPTGAALMNA
SCHEMBL30184734 0.81 TRPV4 (0.48) TSHRPOLBMAPTGAALMNA
SCHEMBL12594025 0.81 ALDH1A1 (0.62) TSHRMAPK1POLBMAPTGAA
SCHEMBL8496034 0.80 SMN1; SMN2 (0.53) MAPK1POLBMAPTKDM4EHTT
SCHEMBL19692878 0.80 MAPT (0.44) TSHRMAPTLMNAHTTKMT2A
SCHEMBL4169872 0.79 MAPK1 (0.47) TSHRMAPK1POLBMAPTLMNA
SCHEMBL4181820 0.78 TSHR (0.55) TSHRMAPK1POLBLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362067-B2 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-29 US disclosed
US-20110059955-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
EP-2233493-A1 Macrolides Pfizer Products Inc. (US) 2010-09-29 EP disclosed
EP-1836211-B1 MACROLIDES PFIZER PROD INC (US) 2010-03-03 EP disclosed
US-7462600-B2 Macrolides PFIZER INC (US) 2008-12-09 US disclosed
EP-1836211-A1 MACROLIDES Pfizer Products Incorporated (US) 2007-09-26 EP disclosed
WO-2006067589-A1 MACROLIDES PFIZER PRODUCTS INC. (US) 2006-06-29 WO disclosed
US-20060135447-A1 Macrolides CHUPAK LOUIS S 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135447-A1 Macrolides LCAT, NOP2, HDAC6 TSHR 3874/4885MAPK1 4016/4885POLB 1605/4885
US-20110059955-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF AVPR1B, AVPR1A, AVPR2 TSHR 383/4885MAPK1 3328/4885POLB 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.